Epitalon

Epitalon has been given to people, but the human record is thin and comes almost entirely from one place. The two Epitalon studies in people described in a 2025 review enrolled 162 patients with retinitis pigmentosa and 75 women in a circadian study, and the retinal trial was run at the St. Petersburg institute whose lead researcher patented the peptide. The famous claim that pineal peptides prolong human life comes from a 2003 study of Epithalamin, a cattle pineal extract, which is a different substance.

The more independent work is in cells. A 2025 study from Brunel University London found Epitalon lengthened telomeres in normal human cells by switching on telomerase, and in two breast cancer cell lines by a separate route called ALT. That is a real mechanism finding. It is not evidence that anyone aged more slowly.

Epitalon is not approved by the FDA, sits on neither FDA compounding category list, and is prohibited in tested sport under WADA's S0 class.

Epitalon, also spelled Epithalon or Epithalone, is a four amino acid peptide: alanine, glutamic acid, aspartic acid, glycine, often written AEDG. It was built to match the amino acid composition of Epithalamin, a polypeptide extract of bovine pineal gland studied in Russia since the 1970s. Vladimir Khavinson patented a method for obtaining it in 2001.

For years nobody had shown that the body makes it. In 2017 the AEDG sequence was reported in pineal gland extract for the first time, so there is now a natural counterpart to the synthetic peptide. Finding a molecule in tissue says nothing about what a dose of it does in a living person.

What the Cell Work Shows

The clearest mechanism data comes from Al-Dulaimi and colleagues at Brunel University London, published in Biogerontology in 2025. They treated two normal human cell types, IBR.3 fibroblasts and HMEC mammary epithelial cells, and two breast cancer lines, 21NT and BT474. Telomeres got longer in all four.

How they got longer differed. In the normal cells, hTERT expression and telomerase activity rose, with telomerase activity up fourfold in IBR.3 and 26-fold in HMEC, and the lengthening took three weeks. In the cancer cells it took four days, telomerase activity did not rise significantly, and the telomeres were extended through ALT, the alternative lengthening of telomeres pathway. The authors note that telomerase in the treated normal cells stayed below the levels already present in the cancer lines.

Beyond Telomeres

The 2025 review by Araj and colleagues lists other reported actions: effects on melatonin synthesis, interleukin-2 mRNA, the mitogenic activity of mouse thymocytes, and enzymes including acetylcholinesterase, butyrylcholinesterase and telomerase. The same authors state plainly that the mechanism of action remains unclear and that it is not known whether these are its only routes of action.

The human lifespan claim belongs to a different substance. The 266-person mortality study gave Epithalamin, a cattle pineal extract. The review notes Epitalon shares properties with it but differs in the intensity of some actions. Citing that study as Epitalon data swaps one product for another.

Longer telomeres in a dish are not a younger body. The Brunel result is a cell culture finding over days to weeks. No source here measured telomere length, ageing or survival in a person given Epitalon.

A melatonin marker is not better sleep. The 75-woman study measured a urinary melatonin metabolite and clock gene expression. Neither is a sleep outcome, and the review's account reports none.

Telomere lengthening also happened in cancer cells. Both breast cancer lines lengthened their telomeres through ALT after treatment. The authors read the normal-cell results as reassuring, but the finding cuts both ways and has not been followed into living tissue.

Volume of studies is not independence. The retinal trial, the patent, the 2003 mortality study and much of the animal work trace to one research network. The clearly independent work so far is in cells.

The retinal trial reported no side effects among Epitalon-treated patients over a course measured in days. That is the whole of the human safety record in these sources, and it comes from the developing institute.

The 2025 review states that information on critical safety issues is missing and that short and long term toxicity, genotoxic activity, carcinogenic potential and drug interactions still need study. Given that cancer cell lines lengthened their telomeres after exposure, the carcinogenicity gap is the one that matters most.

Epitalon is a short synthetic peptide with a long Russian research history, a natural counterpart in pineal tissue, and one solid independent cell study showing it can raise telomerase and lengthen telomeres in normal human cells.

What has been measured in people is narrow: retinal function in one controlled but non-placebo trial, and melatonin and clock gene markers in one small placebo-controlled study. Neither tested ageing, lifespan, sleep quality or recovery. The lifespan figure that circulates comes from a cattle extract.

The useful takeaway is the gap between how often Epitalon is described as a longevity peptide and how little human data exists outside the group that created it.

Not shown to extend human life. The only human mortality data cited used Epithalamin, a bovine extract, not Epitalon.

Not FDA approved, and not on either FDA compounding category list. It left Category 2 on or about 2026-04-22 because the nominators withdrew the nomination, not because FDA resolved its safety concerns, and those concerns remain published. It was reviewed, as both free base and acetate, at the FDA Pharmacy Compounding Advisory Committee meeting of 23-24 July 2026. FDA has published the agenda, roster, voting questions and its own slides but no minutes, transcript or written vote tally, so no outcome is stated here. A committee recommendation would not change any legal status in any case; rulemaking on the full record decides that.

Not permitted in tested sport. It is not named on the WADA Prohibited List, but it is captured by S0 (Non-Approved Substances), which prohibits at all times any pharmacological substance with no current approval by any governmental regulatory health authority for human therapeutic use. Absence from the list is not permission.

Not a sleep aid with evidence behind it. A rise in a urinary melatonin marker is the closest finding, and it is a marker.

I find Epitalon genuinely interesting, and the Brunel cell study is the reason. An outside lab took a peptide surrounded by decades of single-source claims, measured it properly, and found something real: telomerase going up in normal human cells.

What I will not do is let that finding borrow credibility from the lifespan headline, because that headline is about a different substance and comes from the same group that patented this one. People have taken Epitalon, but the human studies measured eyes and melatonin markers, not ageing.

If independent human trials ever measure what the marketing promises, I will write about it with the confidence those trials earn. Until then I hold it at early human data and say clearly where the data stops.